Global Industry Plant Growth Regulators Market Analysis 2012 - 2018

Plant growth regulators (PGR) are those organic compounds which modify and control the physiological processes in a plant. They are of two types - natural or synthetic. The global market for plant growth regulators has shown remarkable progress in recent years and is also showing attractive market potential for the future. The global PGR market is showing great demand in China. China is a manufacturing hub for the PGR market and exports about 60% of its total production. Total output of plant growth regulators in China was registered at USD 256 million in 2009 and is expected to grow in future.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/plant-growth-regulators-market-global-industry-analysis-size-share-growth-trends-and-forecast-2012-2018

The global PGR market could be segmented into three major categories, on the basis of types into: Auxins, Gibberalins, Cytokinnins, Ethylene and Abscisic acid, on the basis of end users into: olericulture, floriculture, pomology, nursery propagation and landscape horticulture, on the basis of applications into: vitro, crop production, post harvest technology, physiology and biochemistry. The market is further segmented by geography into North America, Europe, Asia Pacific and rest of the world regions. The global PGR market is driven by factors such as increasing globalization, rising research and development in agrochemicals and changing lifestyles. Emerging innovative technologies in agriculture and emerging market trends will also act as drivers for the global PGR market.

Some of the key players dominating the global PGR market are Bayer Crop Science, Changzhou Wanxiang Chemicals Co.Ltd, Yancheng Wanxiang Chemicals Co. Ltd, Suzhou Yacoa Chemicals Reagent Co.Ltd, Bluegreen Group company Limited, Xinyi h.k Industrial Co. Ltd, Jiangsu Sevencontinent Green Chemical Co., Ltd., Jiangsu Anpon Electrochemical Co., Ltd., Zhengzhou Zhengshi Chemical Co., Ltd., Yancheng Limin Chemical Co., Ltd., Jiangsu Hormone Research Institute Co., Ltd., Sichuan Guoguang Agrochemical Co., Ltd. and Jiangsu Sword Agrochemicals Co., Ltd. 

To Buy The Copy of This Report Visit:  http://www.marketresearchreports.biz/analysis/171223

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Research Report: Analysis of Global Biochips Market Analysis Industry 2012-2018

Global biochips market is forecasted to reach US$11.4 billion by 2018 with a CAGR of 18.6% during 2012-2018; the massive CAGR is primarily supported by Asia-Pacific followed by the European Union. Among the major industry segments, biochips instruments are expected to exert the highest support to the industry with a CAGR of 20% globally. Microarrays segment accounts for nearly 70% of the industry value while services indicate lesser than 15% of the market value. North America is expected to maintain the highest market share for the biochips industry by 2018; Asian economies are expected to post a large CAGR of 19 percent during 2012-2018. Higher growth rate favors improved industry investments in Asia-Pacific region in comparison with North America and Europe, going ahead.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/analysis-of-global-biochips-industry-2012-2018

Report Focus

The report ‘Analysis of Global Biochips Industry, 2012-2018' reviews the latest biochips market trends with a perceptive attempt to disclose the near-future growth prospects. An in-depth analysis on a geographic basis provides strategic business intelligence for life science sector investments. The study reveals profitable investment strategies for pharmaceutical manufacturers, biotechnology companies, laboratories, Contract Research Organizations (CROs), government organizations and many more in preferred locations.

The report primarily focuses on:

• Emerging Market Trends
• Advancements in the Technological Space
• Market Demand Of The Segments (By-Region)
• Key Growth Areas and Market Size
• Region-Wise Demand Factor
• Key Competitors Edge
• Investment Strategies

Estimates are based on online surveys using customized questionnaires by our research team. Besides information from government databases, company websites, press releases & published research reports are also used for estimates. Estimates have incorporated recessionary impact on the biochips industry.

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/170659

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Recent Report: Global Industry Regenerative Medicine Market Growth 2012 - 2018

Regenerative medicine is an interdisciplinary field which deals with tissue engineering and cell therapy for replacement or regeneration of human cells/tissue/organ function that may have been damaged due to age, disease, trauma or congenital defects. The research in stem cells (embryonic and adult stem cells) has enabled the applications of regenerative medicine in dentistry, dermatology, neurology and orthopedics. The products developed for applications in bone and joint diseases using regenerative medicine include osteobiologics, bone grafts, allografts, cell-based bone graft substitutes, bone morphogenic proteins, demineralized bone matrices (DBMs) and ceramic- and polymer-based bone graft substitutes.

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/regenerative-medicines-market-global-industry-analysis-market-size-market-share-and-forecasts-2012-2018

Shortage of organs available for donation and high organ transplant rejection rates are the major drivers of the global regenerative medicine market. Some of the other drivers include advancing research in nanotechnology, contract manufacturing organizations (CMO’s) and increase in corporate and federal funding. 

Some of the major players in this market are Aastrom Biosciences Inc., Advanced Cell Technology Inc., Athersys Inc, Amgen Inc., Bioheart Inc., Cytori Therapeutics Inc., Celgene Corporation, Geron Corporation, Genzyme Corporation, Osiris Therapeutics, Japan Tissue Engineering Co. Ltd., ThermoGenesis Corporation, and others.

This research report analyzes this market depending on its market segments, major geographies, and current market trends. Geographies analyzed under this research report include 

• North America 
• Asia Pacific 
• Europe
• Rest of the World  

This report provides comprehensive analysis of 

• Market growth drivers 
• Factors limiting market growth
• Current market trends 
• Market structure
• Market projections for upcoming years 

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/138710

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/

Market Overview: China Blood Product Industry Market Share 2012-2015

Plasma is a key raw material of the blood product industry. In August 2011, China shut down 16 plasma stations in Guizhou, resulting in a decrease of 15% in the plasma volume of the year. However, due to the implementation of favorable policies, widening gap between supply and demand, rising product prices and other factors, more than 150 plasma stations in China produced about 3,600 tons of plasma in 2012, up 14.2% year on year. 

From 2012 to mid-2013, new plasma stations of some Chinese enterprises have started plasma collection or obtained plasma collection permits, such as Yuechi plasma station of Jiangxi Boya Bio-Pharmaceutical, Changyuan plasma station of Hualan Bio, and Caoxian plasma station of China Biologic Products. It’s expected that China’s plasma supply tension will be further eased after 2013. 

To Read the Complete Report with TOC Visit: http://www.marketresearchreports.biz/analysis-details/china-blood-product-industry-report-2012-2015

According to the lot release statistics of National Institutes for Food and Drug Control, in the first ten months of 2012, China’s total lot release volume of blood products was about 36.13 million bottles, an increase of 7.1% compared with the full year of 2011. In addition, except human coagulation factor VIII with a decreased lot release volume, other products saw growing release volume. In particular, human immunoglobulin, tetanus immunoglobulin, human fibrinogen, imported human serum albumin witnessed higher growth rates of 321%, 95%, 79%, 45% respectively in the first ten months of 2012. 

However, Chinese blood product enterprises have weak R&D capability, low plasma utilization and fewer product varieties. The domestic market is still dominated by technically undemanding human serum albumin and human immunoglobulin (ph4) for intravenous injection, which accounted for more than 60% of the lot release volume in 2012. 

In order to ease the domestic shortage of blood products, China has allowed the import of human serum albumin and recombinant coagulation factor VIII in recent years. Human serum albumin imports have grown rapidly due to low prices. The lot release volume was 8.51 million bottles in the first ten months of 2012, occupying 47.5% of the lot release volume of such products (43.3% in 2011); Behring, Baxter, Instituto Grifols and Octapharma were top four companies by lot release volume. However, due to high prices and national policy restrictions, the import of recombinant coagulation factor VIII is very small, only Bayer and Baxter products were allowed to be imported as of the end of 2012.

China Blood Product Industry Report, 2012-2015 covers the followings: 

• Plasma volume, plasma station distribution, market size and supply & demand of China blood product industry; 
• Competition pattern, policy environment and import & export of China blood product industry; 
• Market supply & demand and competition pattern of eight categories of blood products including human serum albumin, human immunoglobulin (ph4) for intravenous injection, coagulation factors in China; 
• Development, operation, plasma stations and lot release volume of 12 local blood product producers in China. 

As of the end of 2012, there were about 30 enterprises passing GMP certification and in normal operation, among them, only Hualan Bio, Tiantan Biological Products (including Chengdu Ronsen), Shanghai RAAS, Yuanda Shuyang Pharmaceutical, China Biologic Products have an annual plasma volume of over 300 tons. In 2012, the five enterprises accounted for 56.1% of China’s total plasma volume, and about 30% of China’s blood product market revenue. 

Guangdong Shuanglin Bio-pharmacy, the sixth place holder, had nine plasma stations (three under construction) in 2012, with a plasma volume of about 247 tons and blood product revenue of RMB 431 million. The company has held the largest lot release volume of rabies immunoglobulin in recent years. Jiangxi Boya, though occupying a small market share (1.8% in 2012 by sales), has seven plasma stations, with output and sales volume expected to be further enhanced in the future.

To Buy The Copy of This Report Visit: http://www.marketresearchreports.biz/analysis/170322  

About Us

MarketResearchReports.Biz is the most comprehensive collection of market research reports. MarketResearchReports.Biz services are especially designed to save time and money of our clients. We are a one stop solution for all your research needs, our main offerings are syndicated research reports, custom research, subscription access and consulting services. We serve all sizes and types of companies spanning across various industries.

Contact

M/s Sheela

90 Sate Street, Suite 700

Albany, NY 12207

USA – Canada Toll Free: 866-997-4948

Email: sales@marketresearchreports.biz

Website: http://www.marketresearchreports.biz/

Blog: http://industry-research-reports.blogspot.com/